Children; Infection
Conditions
Brief summary
This study is based on the hypothesis that the pharmacokinetics of anti-infective drugs in children are different from adults. We aim to study the population pharmacokinetics of children receiving the anti-infective drugs for treatment of infectious diseases. In this study, we will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. In addition, we also want to correlate use of anti-infective drugs with treatment effectiveness and incidence of adverse effects in children. This novel knowledge will allow better and more rational approaches to the treatment of infectious diseases in children. It will also set the foundation for further studies to improve anti-infective drug therapies for children.
Detailed description
1.Establish population pharmacokinetic (PPK) models of each anti-infective drug in children by nonlinear mixed effect modeling (NONMEM). 1. At different timepoint after antibiotic administration, plasma samples of 100 children will be collected from neonatal intensive care unit (NICU) and pneumology department for each drug. The clinical information includes demography, medication, concentration data, blood biochemical parameters and so on . 2. Plasma samples will be tested by high performance liquid chromatography (HPLC). 3. PPK models of antibiotics will be established by NONMEM program. 4. The reliability and stability of the PPK model will be evaluated by 1000 times of Bootstrap procedure and normalized predictive distribution error (NPDE). 2.Evaluation of the clinical feasibility and safety of individualized dosing. 1. According the results of PPK models, we will use dosages recommended in models to cure children infectious diseases in prospective studies. For each antibiotic, 50 children will be collected. 2. We will compare the therapeutic effects and safety between children with conventional therapies and children with individualized therapies, including proportions of children with effective drug concentration, improvement speed of of children, liver and kidney functions of of children, adverse reactions of drugs and so on.
Interventions
DRUGcephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
Sponsors
Shandong University
Hopital Universitaire Robert-Debre
Rennes University Hospital
Beijing Children's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Days to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children (0-18 years old) with anti-infective therapy against infectious diseases. * The anti-infective therapy includes drugs commonly used in children infectious diseases, for example, cephalosporins (such as latamoxef, ceftazidime, ceftriaxone and so on), penicillins (such as penicillin, amoxicillin, ampicillin and so on), macrolides (such as erythromycin, azithromycin and so on), carbapenems (sucn as meropenem, imipenem and so on) and antiviral drugs (such as ganciclovir, acyclovir and so on). * Children infectious diseases include pneumonia, sepsis, purulent meningitis and other diseases with infection. * Informed consent signed by the parents and/or guardians.
Exclusion criteria
* Anti-infective drugs aren't involved in the therapies of children. * It is unable to provide complete medical records or the current condition cannot accept the study process. * Patients are allergic to anti-infective drugs. * Parents and/or guardians do not agree to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum concentration (Cmax) | up to 4 weeks | Cmax is a term used in pharmacokinetics refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| time to achieve maximum concentration (Tmax) | up to 4 weeks | Tmax is the term used in pharmacokinetics to describe the time at which the Cmax is observed. |
| absorption rate constant (ka) | up to 4 weeks | Ka is the rate constant of drug absorption. |
| elimination rate constant (kel) | up to 4 weeks | The elimination rate constant is a value used in pharmacokinetics to describe the rate at which a drug is removed from the system. |
| half-life (t1/2) | up to 4 weeks | Half-life is the time required for a quantity to reduce to half its initial value. |
Countries
China
Contacts
Primary ContactA-Dong Shen, Master
Outcome results
None listed